SCHEMBL986584

SCHEMBL986584

COc1c(C)cc(C(=O)Cl)cc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
TUBB4A P04350 1/20 0.44
TUBB P07437 1/20 0.44
TUBA3C P0DPH7 1/20 0.44
TUBA1B P68363 1/20 0.44
TUBA4A P68366 1/20 0.44
TUBB4B P68371 1/20 0.44
TUBB3 Q13509 1/20 0.44
TUBB2A Q13885 1/20 0.44
TUBB8 Q3ZCM7 1/20 0.44
TUBA3E Q6PEY2 1/20 0.44
TUBA1A Q71U36 1/20 0.44
TUBA1C Q9BQE3 1/20 0.44
TUBB6 Q9BUF5 1/20 0.44
TUBB2B Q9BVA1 1/20 0.44
TUBB1 Q9H4B7 1/20 0.44
TAS1R3 Q7RTX0 3/20 0.44
TAS1R1 Q7RTX1 3/20 0.44
CYP2C19 P33261 1/20 0.40
TPMT P51580 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14218378 0.88 TPMT (0.47) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL11435411 0.82 TUBB4A (0.54) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL312132 0.80 TPMT (0.55) ALDH1A1TAS1R3TAS1R1TPMTKDM4E
SCHEMBL2796551 0.80 LMNA (0.52) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL349440 0.79 KDM4E (0.46) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL7987712 0.79 PTPN1 (0.43) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL985523 0.78 ALDH1A1 (0.61) ALDH1A1TAS1R3TAS1R1TPMTKDM4E
SCHEMBL219096 0.78 TUBB4A (0.55) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1005872 0.78 TSHR (0.55) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4311603 0.78 TPMT (0.39) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022196258-A1 ONIUM SALT, PHOTOACID GENERATOR, COMPOSITION, AND METHOD FOR PRODUCING DEVICE USING SAME 東洋合成工業株式会社 2022-09-22 WO disclosed
US-10005750-B2 Developing potent urate transporter inhibitors: compounds designed for their uricosuric action J-PHARMA CO., LTD. (JP) 2018-06-26 US disclosed
EP-2729472-B1 CARBOXYLIC ACID DERIVATIVES WITH AN OXAZOLO[4,5-C]PYRIDINE RING SANOFI SA (FR) 2016-08-24 EP disclosed
US-9321787-B2 Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring SANOFI (FR) 2016-04-26 US disclosed
EP-2729473-B1 CARBOXYLIC ACID DERIVATIVES WITH AN OXAZOLO[5,4-B]PYRIDINE RING SANOFI SA (FR) 2015-11-25 EP disclosed
EP-2729475-B1 Carboxylic acid derivatives with an oxazolo[4,5-d]pyrimidine ring SANOFI SA (FR) 2015-06-10 EP disclosed
US-9040544-B2 2,5-substituted oxazolopyrimidine derivatives SANOFI (FR) 2015-05-26 US disclosed
EP-2729471-B1 CARBOXYLIC ACID DERIVATIVES WITH AN OXAZOLO[5,4-D]PYRIMIDINE RING SANOFI SA (FR) 2015-05-06 EP disclosed
US-8907093-B2 Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring SANOFI (FR) 2014-12-09 US disclosed
US-8846692-B2 Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring SANOFI (FR) 2014-09-30 US disclosed
WO-2011086077-A1 CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING SANOFI-AVENTIS (FR) 2011-07-21 WO disclosed
WO-2011086081-A1 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES SANOFI-AVENTIS (FR) 2011-07-21 WO disclosed
WO-2011086075-A1 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES SANOFI-AVENTIS (FR) 2011-07-21 WO disclosed
WO-2011086079-A1 CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING SANOFI-AVENTIS (FR) 2011-07-21 WO disclosed
US-7875631-B2 e.g.1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline; to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of insulin-like growth factor-1 receptor is observed ANALYTECON S.A. (CH) 2011-01-25 US disclosed
US-20100137445-A1 PLANT DISEASE CONTROL AGENT, AND PLANT DISEASE CONTROL METHOD SUMITOMO CHEMICAL COMPANY ,LIMITED 2010-06-03 US disclosed
US-4024273-A Coronary vasodilator and anti-anginal compositions comprising substituted benzofurans and benzothiophenes and methods of producing coronary vasodilation and anti-anginal activity SMITHKLINE CORPORATION (US) 1977-05-17 US disclosed
US-4001426-A HAVING CORONARY VASODILATOR ACTIVITY SMITHKLINE CORPORATION (US) 1977-01-04 US disclosed
US-3975537-A SUBSTITUTED BENZOFURANS SMITH KLINE (US) 1976-08-17 US disclosed
US-3947470-A CORONARY VASODILATORS, TREATMENT OF ANGINA PECTORIS SMITHKLINE CORPORATION (US) 1976-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10005750-B2 Developing potent urate transporter inhibitors: compounds designed for their uricosuric action SLCO2B1, SLCO2A1, SLC10A6 ALDH1A1 1289/4885TUBB4A 4711/4885TUBB 4564/4885
US-20100137445-A1 PLANT DISEASE CONTROL AGENT, AND PLANT DISEASE CONTROL METHOD CBR3, CBR1, HDHD5 ALDH1A1 2677/4885TUBB4A 1594/4885TUBB 2097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.